Last reviewed 2026-04-23 · How we verify

AGN-199201 ophthalmic solution

AGN-199201 is a selective prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.

AGN-199201 is a selective prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure. Used for Glaucoma or ocular hypertension (Phase 2).

At a glance

Mechanism of action

The drug binds to FP receptors in the eye, enhancing drainage of aqueous humor through the uveoscleral (unconventional) pathway. This mechanism reduces intraocular pressure, which is the primary pathogenic factor in glaucoma and ocular hypertension. Prostaglandin analogs are a well-established drug class for glaucoma management.

Approved indications

• Glaucoma or ocular hypertension (Phase 2)

Common side effects

• Conjunctival hyperemia
• Iris pigmentation changes
• Eyelash growth
• Eye irritation

Key clinical trials

• A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia (PHASE2)
• A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia (PHASE2)
• Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AGN-199201 ophthalmic solution CI brief — competitive landscape report
• AGN-199201 ophthalmic solution updates RSS · CI watch RSS
• Allergan portfolio CI